Michael Jeltsch

from Wikipedia, the free encyclopedia

Michael Jeltsch (born July 28, 1969 in Hemer ) is a German-Finnish biochemist . He is an Associate Professor at the University of Helsinki and an author in the field of vascular biology.

Career

Michael Jeltsch wrote both his doctoral thesis and his habilitation while working with Kari Alitalo at the Molecular / Cancer Biology Lab at the University of Helsinki in Finland. He worked as a research assistant in the biotechnology company Lymphatix Ltd. (which was later acquired by Ark Therapeutics) and Vegenics Ltd., where he was involved in the development of cancer drugs. For a short time he was a postdoctoral fellow at the Wihuri Research Institute before he was recruited as a group leader by the University of Helsinki in 2013. His laboratory is part of the Translational Cancer Biology Research Program and the Institute of Biomedicine at the University of Helsinki.

Scientific work

Michael Jeltsch was the first to show that VEGF-C and VEGF-D are the main factors for lymphatic vessel growth.
Today his research focuses on the development of anticancer drugs whose target molecules are important for the lymphatic system. With his publications he has also contributed to the field of cell biology , transgenesis and the development, recombinant production and purification of proteins. In 2006 he developed a synthetic super growth factor based on a library of hybrid molecules between VEGF and VEGF-C, which he had generated using a newly developed method (non-random DNA family shuffling).

Awards

In 1997 he was awarded the Medix Prize from the Minerva Foundation Institute for Medical Research for the best biomedical publication of the year in Finland.

In 2003 he received the Mandatum Prize for the best PhD thesis in the field of biotechnology in Finland and in 2015 he received the "Best Paper Award" in the basic research category from Circulation, the journal of the American Heart Association for his work published in 2014 in who explained the molecular mechanism that underlies Hennekam syndrome .

Individual evidence

  1. ^ University of Helsinki: Jeltsch Lab . 2016 ( jeltsch.org ).
  2. ^ List of Publications at Web of Science (Thomson Reuters). Retrieved June 14, 2019 .
  3. ↑ M. Jeltsch, A. Kaipainen, V. Joukov, X. Meng, M. Lakso, H. Rauvala, M. Swartz, D. Fukumura, RK Jain, K. Alitalo: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice . In: Science . tape 276 , no. 5317 , 1997, pp. 1423-1425 .
  4. ^ SJ Oh, M. Jeltsch, R. Birkenhäger, JE McCarthy, HA Weich, B. Christ, K. Alitalo, J. Wilting: VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane . In: Developmental Biology . tape 188 , no. 1 , 1997, p. 96-109 .
  5. ^ MG Achen, M. Jeltsch, E. Kukk, T. Mäkinen, A. Vitali, AF Wilks, K. Alitalo, SA Stacker: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) . In: Proceedings of the National Academy of Sciences . tape 95 , no. 2 , 1998, p. 548-553 .
  6. ↑ Michael Jeltsch, Sawan Kumar Jha, Denis Tvorogov, Andrey Anisimov, Veli-Matti Leppänen: CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation . In: Circulation . tape 129 , no. 19 , May 13, 2014, ISSN  1524-4539 , p. 1962-1971 , doi : 10.1161 / CIRCULATIONAHA.113.002779 , PMID 24552833 .
personal data
SURNAME Jeltsch, Michael
BRIEF DESCRIPTION German-Finnish biochemist and molecular biologist
DATE OF BIRTH July 28, 1969
PLACE OF BIRTH Hemer